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UTE WOLF-SCHNURRBUSCH, GIOVANNI STAURENGHI, URSULA SCHMIDT-ERFURTH, AND
FRANK G. HOLZ PURPOSE: To determine the safety and efficacy of AL-
8309B (tandospirone) in the management of patients
with geographic atrophy (GA) secondary to age-related
macular degeneration (AMD) and obtain standardized
data on GA lesion growth progression.
 DESIGN: Prospective, controlled, double-masked, ran-
domized, multicenter phase 3 clinical trial.
 METHODS: SETTING: Forty-eight clinical sites.
PATIENTS: Patients with GA associated with AMD were
enrolled. All patients were followed for a minimum of
30 months, and up to 36 months. INTERVENTION PROCE-
DURES: Patients were randomized (1:1:1) to receive AL-
8309B ophthalmic solution 1.0%, 1.75%, or vehicle,
administered as a twice-daily topical ocular drop. MAIN
OUTCOME MEASURES: The primary efficacy endpoint was
mean annualized lesion enlargement from baseline as
assessed with fundus autofluorescence (FAF) imaging.
 RESULTS: A total of 768 eyes of 768 patients were
enrolled and treated with AL-8309B 1.0% (n [ 250),
AL-8309B 1.75% (n [ 258), or vehicle (n [ 260).
An increase in mean lesion size was observed in both
the AL-8309B and vehicle treatment groups, and growth
rates were similar in all treatment groups. Annualized
lesion growth rates were 1.73, 1.76, and 1.71 mm2 for
AL-8309B 1.0%, AL-8309B 1.75%, and vehicle,
respectively.
 CONCLUSIONS: AL-8309B 1.0% and 1.75% did not
affect lesion growth in eyes with GA secondary to
AMD. There were no clinically relevant safety issues
identified for AL-8309B. The large natural historyr publication Aug 18, 2015.
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G
EOGRAPHIC ATROPHY (GA) IS THE ADVANCED
form of dry age-related macular degeneration
(AMD), a progressive degenerative disease that
is associated with severe visual impairment and enlarge-
ment of scotomas. The central field visual loss caused by
GA is progressive, irreversible, and bilateral in the majority
of patients.1,2 AMD affects approximately 8 million people
in the United States alone, with an annual incidence of
almost 500 000, and is responsible for 20% of all the
cases of severe vision loss in North America.3–6 The
prevalence of GA increases with age and approximately
quadruples per decade beyond age 50. The estimated
prevalence of GA in populations of European ancestry at
70 years of age is 0.7%, rising to 2.9% at 80 years of age
and 11.3% at 90 years of age.4 In the year 2040, the preva-
lence of GA in the overall population is expected to
increase by 75%.7
Anatomically, GA is characterized by atrophy of the
photoreceptors, retinal pigment epithelium (RPE), and
choriocapillaris. Various changes that include thickening
of the Bruch membrane and deposition of waste products,
lipofuscin accumulation in the RPE, RPE hypopigmenta-
tion, and drusen formation underneath the RPE cell mono-
layer precede photoreceptor loss in GA. Large and
confluent drusen represent a significant risk factor.8
GA pathogenesis is thought to be multifactorial;
biochemical, histologic, and genetic studies have impli-
cated several mechanisms, including oxidative damage,
chronic inflammation, and excessive accumulation of
lipofuscin. Several lines of evidence support the critical
roles played by oxidative stress and inflammation in the
development and progression of AMD. Oxidized proteins
and protein adducts (eg, carboxyethylpyrrole) have been
detected by proteomic analysis in drusen of eyes with
AMD. Additionally, oxidation products detected by
immunohistochemistry have been observed in the retina0002-9394
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of eyes with advanced AMD and GA.9–11 Epidemiologic
studies in elderly patients have found that smoking is a
risk factor, whereas a diet rich in antioxidants is a risk
reduction factor for the development of AMD.12,13
Lastly, the Age-Related Eye Disease Study (AREDS)
showed that supplements containing antioxidant vita-
mins and zinc reduced the risk for progression of earlier
stages of AMD, although the effect on GA was not stud-
ied.14 Based on this body of evidence, drugs that have
an antioxidant and/or neuroprotective role are strong
candidates for GA therapy.
Currently, there are no approved treatments to prevent
the worsening of GA or the associated decline in visual
function. This treatment paucity is mainly owing to the
lack of suitable molecular targets or animal models. Apart
from general lifestyle advice (dietary, vitamins, etc), there
are no specific interventions to slow or reverse progression
from early AMD to late disease stages.7 In addition, certain
anti–vascular endothelial growth factor medications, used
for the treatment of neovascular AMD, may in fact worsen
the progression of GA, as studies in mice have shown that
these treatments can interfere with the ocular vasculature
and may be associated with RPE and choroidal atrophy.15
In a preclinical study, where a model of retinal degener-
ation was used to test a number of neuroprotective agents,
5-HT1A agonists were among the most potent agents eval-
uated.16,17 Although 5-HT1A agonists have primarily been
used to treat anxiety and depression, this class of com-
pounds is known for its cell-protective activity following
traumatic brain injury,18,19 in excitotoxicity induced by
N-methyl-D-aspartate,20 and in a variety of central nervous
system ischemia models.21–23 Because these studies
suggested a possible neuroprotective role of 5-HT1a recep-
tor activation, a search was initiated for a clinical-stage
5-HT1a agonist. Subsequently, a formulation (AL-
8309B) for potential topical ocular use in the management
of GA was developed. In albino and pigmented rats
subjected to a severe acute photo-oxidative stress, AL-
8309B protected photoreceptors and RPE cells in a dose-
dependent manner.16
Based on the preclinical data, the Geographic Atrophy
Treatment Evaluation (GATE) phase 3 clinical trial pro-
gram (NCT00890097) was initiated to evaluate the safety
and efficacy of AL-8309B in patients with GA. In the pre-
sent report, we describe the safety and efficacy of AL-8309B
when given topically to treat GA associated with non-
neovascular AMD.METHODS
THE GATE STUDY WAS A PROSPECTIVE, CONTROLLED,
double-masked, randomized (1:1:1), multicenter phase 3
interventional clinical trial designed to determine theVOL. 160, NO. 6 TANDOSPIRONE TRIAL FOR USEsafety and efficacy of AL-8309B ophthalmic solution vs
vehicle administered as a twice-daily topical eye drop to
treat GA secondary to AMD. The study was performed
in compliance with the ethical principles of the Declara-
tion of Helsinki and Good Clinical Practice and multiple
Institutional Review Boards (IRBs) including a central
IRB (Sterling IRB) and institutional and local IRBs
(country-specific). Patients provided signed informed
consent. This was the first-in-human proof-of-concept
study conducted to establish efficacy relative to vehicle.
Investigational New Drug (IND) number 101095 was
registered in the clinical trials database of the National
Institute of Health (ClinicalTrials.gov Identifier:
NCT00890097).
Included in the study were patients who were aged 55
years or older with GA secondary to AMD with no evi-
dence of choroidal neovascularization in the study eye,
those with a well-demarcated area of atrophy (if multi-
focal, at least 1 focal lesion must have been equal to or
larger than 1.25 mm2), and a total lesion size of less
than or equal to 20 mm2. The study eye also had to
have hyperautofluorescence adjacent to the area of atro-
phy, a best-corrected visual acuity (BCVA) of 35 letters
(20/200 Snellen) or better, and clear ocular media and
adequate pupillary dilation to allow high-quality photo-
graphic imaging.
Excluded from the study were patients with ocular dis-
ease other than nonexudative AMD in the study eye that
may confound assessment of GA lesions, or that may affect
central visual acuity (eg, branch retinal vein occlusion, dia-
betic retinopathy, and uveitis); a history of cataract surgery
in either eye within the past 3 months of screening or a his-
tory or evidence of serious ocular trauma or intraocular sur-
gery (laser in situ keratomileusis, keratoplasty) in either eye
within the past 6 months of screening; and current or pre-
vious use of serotonin receptor agonists, selective serotonin
reuptake inhibitors, selective serotonin/epinephrine reup-
take inhibitors, monoamine oxidase inhibitors, and trip-
tans within 30 days of screening.
The first patient was enrolled April 28, 2009 and enroll-
ment ended in December 2009. The study was completed
on May 31, 2012. Sequential patient numbers were
randomly assigned to treatment groups according to a
randomization schedule generated by the Alcon statistical
programming group. The randomization was blocked
within center to ensure balanced treatment groups within
each center. Patients were randomized at visit 2 (day 0)
and had follow-up visits to the clinic at weeks 2, 4, and
12 and every 12 weeks thereafter for the study duration.
The patients and investigators, as well as all study and
Alcon personnel who had contact with investigators or
patients, were masked with regard to treatment assign-
ments while the study was in progress. Patients were to
be followed for up to 36 months with a minimum follow-
up for all patients of 30 months. However, as per the1227IN GEOGRAPHIC ATROPHY
TABLE 1.Demographics and Ocular Characteristics of Patients Involved in the Geographic Atrophy Treatment Evaluation Clinical Trial
Characteristic
AL-8309B 1.0%
N ¼ 252
AL-8309B 1.75%
N ¼ 259
Vehicle
N ¼ 261
Total
N ¼ 772
Male, n/N (%) 122/252 (48) 97/259 (37) 114/261 (44) 333/772 (43)
Age (y), mean (SD) 77.9 (8.0) 78.3 (7.7) 78.8 (7.1) 78.3 (7.6)
Race, n/N (%), white 243/252 (96) 253/259 (98) 251/261 (96) 747/772 (97)
Iris color, n (%), blue 81 (32) 102 (39) 92 (35) 275 (36)
Study eye, n (%), right 142 (56) 138 (53) 148 (57) 428 (55)
Months from diagnosis
n 250 258 259 767
Mean (SD) 42.4 (41.7) 44.7 (43.5) 45.1 (42.7) 44.1 (42.6)
Baseline lesion size (mm2), mean (SD) 7.4 (4.6) 7.5 (4.4) 7.6 (4.5) 7.5 (4.5)
AL-8309B 1.75% ¼ AL-8309B ophthalmic solution, 1.75%; AL-8309B 1.0% ¼ AL-8309B ophthalmic solution, 1.0%; Vehicle ¼ AL-8309B
ophthalmic solution vehicle.
Column header counts and denominators are the number of randomized patients.recommendation from the Data Monitoring Committee
(DMC) the study was discontinued after 600 patients
had completed month 24 visit assessment, because the
treatment was determined to be ineffective.
Both eyes (study eye and nonstudy eye) were dosed with
study medication. If both eyes met the criteria, the eye
with the best visual acuity at the screening visit (visit 1)
was designated as the study eye. If both eyes met the
criteria and had the same visual acuity at the screening
visit (visit 1), the dominant eye was designated as the
study eye. Patients instilled 1 drop of study medication
into each eye twice daily with a dosing interval of approx-
imately 12 h.
Confocal scanning laser ophthalmoscopy blue light
fundus autofluorescence (FAF) was performed using
HRAc, HRA2, or Spectralis (Heidelberg Engineering,
Heidelberg, Germany). FAF and color fundus photog-
raphy (CFP) images were collected at baseline and at
minimum every 6 months for up to 36 months. Fluores-
cein angiograms (FAs) were collected at the screening
visit only. Fluorescein angiography and CFP were
performed with standard fundus cameras with a mini-
mum resolution of 2000 3 2000 pixels. To minimize
variability, certification of the assessment procedures
and examiners at each investigative site occurred prior
to any study eye image evaluation. Fluorescein angio-
graphic, CFP, and FAF images were transmitted from
study sites to the Duke Reading Center (central
reading center) through a secure, web-based portal. Im-
ages were then assigned to trained Duke Reading Cen-
ter or GRADE Reading Center readers, who
independently assessed the FAs, CFPs, and FAF images
for study eligibility and measured lesion size at study
visits to determine lesion growth. Readers measured
the atrophic lesion areas with semi-automated software1228 AMERICAN JOURNAL OF(RegionFinder; Heidelberg Engineering, Heidelberg,
Germany), as previously described.24
To monitor ocular safety, BCVA was assessed, as deter-
mined by the number of letters read on an Early Treatment
Diabetic Retinopathy Study (ETDRS) chart. In addition, a
complete ophthalmic examination was performed that
included slit-lamp examination, dilated fundus examina-
tion by ophthalmoscopy, and intraocular pressure (IOP)
measurement.
Four interim analyses were performed. The first interim
analysis was performed to assess patient safety afterw200 pa-
tients had completed 6months of follow-up. The second and
third analyses were primarily administrative to allow for an
assessment of the conditional power associated with the pri-
mary efficacy hypothesis. These 2 interim analyses were
performed after w600 evaluable patients had completed
12 and 18 months of follow-up, respectively. The fourth
interim analysis was performed after all evaluable patients
had completed 24months of follow-up.At the finalmeeting,
the DMC recommended the study be stopped for futility.
 STATISTICAL ANALYSIS: The primary efficacy endpoint
was the mean annualized lesion growth rate from baseline,
as assessed with FAF imaging. Lesion growth rate was
defined as the change in lesion size from baseline to months
6, 12, 15, 18, 24, and 30. A longitudinal random-effects
regression model (from a linear mixed model using an un-
structured covariance matrix) was used to estimate the
annualized lesion growth rate, taking into consideration
that follow-up occurred over the 24-month period, after
which the study was terminated. Secondary endpoints
included mean BCVA change from baseline and mean
changes from baseline in the near activity scores, distance
activity, and vision-specific dependency subscales of the
National Eye Institute 25-Item Visual FunctionDECEMBER 2015OPHTHALMOLOGY
FIGURE 1. CONSORT flow diagram for patients involved in the Geographic Atrophy Treatment Evaluation (GATE) trial. Patient
progress through the GATE trial is indicated in the diagram, including final N values for each study arm. AE, adverse event.Questionnaire (NEI VFQ-25). The VFQ-25 data were not
analyzed because of the early study termination. Statistics
including number (N), mean, standard deviation, mini-
mum, maximum, and quartiles were provided for the pri-
mary and secondary endpoints at each visit.RESULTS
THE PATIENT DEMOGRAPHICS AND BASELINE CHARACTER-
istics are provided in Table 1. A total of 772 patientsVOL. 160, NO. 6 TANDOSPIRONE TRIAL FOR USEwho met eligibility criteria (some of whom were active par-
ticipants in an earlier natural history study, the Geographic
Atrophy Progression [GAP] clinical trial; ClinicalTrials.
gov identifier: NCT00599846) were enrolled at 48 global
clinical sites. Of 772 randomized patients, 768 were treated
(AL-8309B 1.0%, n ¼ 250; AL-8309B 1.75%, n ¼ 258;
vehicle, n¼ 260) (Figure 1). Patient disposition is also pro-
vided in Figure 1. The majority of patients were white and
the mean age was 78 years. In 55% of patients, the right eye
was chosen as the study eye and the mean GA duration in
the study eye, approximately 44 months, was similar among
the 3 groups.1229IN GEOGRAPHIC ATROPHY
FIGURE 2. Lesion size distribution and change from baseline by visit in the study eye in the Geographic Atrophy Treatment Eval-
uation trial. Box plots show distribution (top) and change from baseline (bottom) of lesion size (mm2) by visit in the study eye after
treatment with AL-8309B vs vehicle. Counts are subjects with baseline and post-baseline data at the specified visit. D, day; M,
month.The mean total lesion size at baseline in the study eye
was 7.4 mm2 in the AL-8309B 1.0% group, 7.5 mm2 in
the AL-8309B 1.75% group, and 7.6 mm2 in the vehicle
group (Table 1). An increase in the mean lesion size was
observed in both the AL-8309B and vehicle treatment
groups (Figure 2) and was identical in patients treated
with AL-8309B compared to those treated with vehicle
(Figure 3). The annualized lesion growth rate for
AL-8309B 1.0%, AL-8309B 1.75%, and vehicle was 1.73,
1.76, and 1.71 mm2, respectively (Table 2).
There was a small decrease in mean study eye BCVA
during the study (Figure 4). The BCVA change did not
differ significantly among patients treated with AL-8309B
compared to those that were treated with vehicle. The per-
centage of eyes with a 10-letter or greater decrease when
treated with AL-8390B 1.0% and 1.75% was 30% and
29%, respectively, at month 24, and 38% and 35%, respec-
tively, at month 30.
There were no clinically important differences among
treatment groups in the frequency of ocular adverse events
(AEs) based on individual system organ classes (Table 3).
Common AEs (>_4% in any 1 treatment class) included
reduced visual acuity, cataracts, eye irritation, eye pain,
blepharitis, choroidal neovascularization, macular degener-
ation, blurred vision, and increased lacrimation (Table 3).
These events were generally comparable among AL-8309B
and vehicle treatment groups. However, AEs in the study
eye were slightly more frequent for patients receiving1230 AMERICAN JOURNAL OFAL-8309B 1.0% or 1.75% compared to vehicle for the
following ocular AEs: eye irritation (8%, 10% vs 3%),
eye pain (6%, 7% vs 3%), blepharitis (5%, 7% vs 3%),
and increased lacrimation (3%, 6% vs 1%). Overall,
AL-8309B had a favorable ocular safety profile with a
serious adverse event (SAE) frequency of <1%.DISCUSSION
IN THE CURRENT REPORT, WE ASSESSED THE EFFECT OF AL-
8309B compared to placebo on the growth rate of GA le-
sions in eyes with AMD. The lesion growth rate was
approximately 1.75 mm2 per year, and did not differ,
regardless of whether patients were treated with AL-
8309B or vehicle. AL-8309B was generally tolerated, and
there were few SAEs associated with its use.
We used GA lesion growth rate rather than visual acuity
changes tomonitor the therapeutic effect of AL-8309B. For
some diseases, such as diabetic macular edema and neovas-
cular AMD, central visual acuity loss is a useful biomarker
of disease progression. Similarly, in eyes with GA that af-
fects the central fovea, there may be significant associated
central visual acuity loss that results from dense, irrevers-
ible scotomas. However, in eyes with foveal-sparing GA,
there may be minimal effects on central visual acuity.
Furthermore, BCVA does not correlate well with the sizeDECEMBER 2015OPHTHALMOLOGY
FIGURE 3. Mean change from baseline (BL) in lesion size in the study eye in the Geographic Atrophy Treatment Evaluation trial.
Growth rate (mm2, ± SE) of the lesion size with treatment of AL-8309B and vehicle. Lines connect the mean of the lesion size at each
visit. Counts are subjects with baseline and post-baseline data at the specified visit. SE, standard error; M, month.
TABLE 2. Annualized Lesion Growth Rate After Treatment With AL-8309B or Vehicle in the Geographic Atrophy Treatment Evaluation
Clinical Trial
AL-8309B 1.0%
N ¼ 250
AL-8309B 1.75%
N ¼ 258
Vehicle
N ¼ 260
Mean (95% CI) yearly change from baseline 1.725 (1.595, 1.855) 1.758 (1.626, 1.890) 1.707 (1.585, 1.830)
Mean (95% CI) difference from vehicle 0.017 (0.161, 0.196) 0.051 (0.129, 0.231)
AL-8309B 1.75% ¼ AL-8309B ophthalmic solution, 1.75%; AL-8309B 1.0% ¼ AL-8309B ophthalmic solution, 1.0%; CI ¼ confidence inter-
val; Vehicle ¼ AL-8309B ophthalmic solution vehicle.
Column header counts are the number of randomized and treated patients.
Lesion sizes reported in mm2.
Results estimated from a longitudinal random-effects regression model.of a GA lesion; therefore, alternative clinical endpoints
have been sought. For example, GA lesion growth rate
(as was used in the present study), drusen, progression of in-
termediate to advanced AMD, reading speed, dark adapta-
tion, microperimetry, and contrast sensitivity are alternate
endpoints that are used to assess the anatomic and func-
tional effects of GA disease progression.25VOL. 160, NO. 6 TANDOSPIRONE TRIAL FOR USEThe observed annual growth rate in this study, approxi-
mately 1.75 mm2, was slightly higher than that reported in
the Fundus Autofluorescence Imaging in Age-Related
Macular Degeneration (FAM) study (median 1.52 mm2),
which examined FAF patterns associated with GA and
the impact on GA progression rates over time,26 and in
the Beaver Dam Eye Study, (6.4 mm2 over 5 years, average1231IN GEOGRAPHIC ATROPHY
FIGURE 4. Distribution and change in best-corrected visual acuity (BCVA) from baseline after AL-8309B treatment vs vehicle in
the Geographic Atrophy Treatment Evaluation trial. Box plots show the changes in BCVA in Early Treatment Diabetic Retinopathy
Study (ETDRS) letters (top) and BCVA change from baseline (bottom) after treatment with AL-8309B vs vehicle. Counts are sub-
jects with baseline and post-baseline data at the specified visit. D, day; W, week.1.3 mm2 per year), which examined the change in size and
location of GA lesions.1,3 In clinical studies, the GA
growth rates vary widely among individuals and may
range from 1.2 mm2 to 2.8 mm2 per year.3 The reason for
this variability is not understood, and may include inherent
study population differences, different trial protocols
(including different measurement methods), follow-up pe-
riods, or different genotype distributions for which the trial
population is not specified or powered. This study is signif-
icant because the standardized follow-up and the compre-
hensive analysis in the absence of any therapeutic effects
nonetheless provides robust GA natural history data that
will inform future analyses of the correlation of GA lesion
size, morphology, growth rate, and location with visual
function.
For the primary study endpoint, given the similar
growth rates between the treated and untreated eyes,
the data suggest a lack of treatment effect by AL-8309B
given in the topical formulation used in the study. The
mean visual acuity change, a key secondary endpoint,
was similar in all treatment groups, further supporting a
lack of drug efficacy. Definitive reasons for the lack of ef-
ficacy within this study are unknown, but possible expla-
nations include the following: the topical AL-8309B1232 AMERICAN JOURNAL OFadministration may not have provided adequate posterior
segment drug delivery; tested doses may have been too low
to exert a therapeutic effect; the drug may not have been
administered during an optimal stage of disease; and/or
the trial design was based on experimental animal models
of degenerative disease, which may not reflect human GA
pathogenesis. Furthermore, autofluorescence topography
differs distinctly from the topography of age-related rod
loss, suggesting that lipofuscin, a target of AL-8309B,
may not induce RPE apoptosis.27 The latter 2 points could
have accounted for an inherent lack of drug treatment ef-
fect; the duration of the study and the high attrition rate
may also have played a role in the lack of drug efficacy.
Endpoints that capture anatomic changes earlier may
have helped identify more subtle lesion progression.
Spectral-domain optical coherence tomography (SD
OCT) can provide high-resolution cross-sectional anatomic
images of relevant biological tissues such as the neurosen-
sory retina and the choroid. In contrast, FAF offers en
face imaging. However, SD OCT, which complements in-
formation obtained from FAF, and which may have pro-
vided insights into drug effect and longitudinal
pathophysiology of GA, was not used in this study.28
Furthermore, an analysis of drug effect on growth rate,DECEMBER 2015OPHTHALMOLOGY
TABLE 3. Frequent Adverse Events in the Study Eye After
Treatment With AL-8309B or Vehicle in the Geographic
Atrophy Treatment Evaluation Clinical Trial
AL-8309B 1.0%
N ¼ 250
AL-8309B 1.75%
N ¼ 258
Vehicle
N ¼ 260
Any ocular AEs in the
study eye
166 (66) 172 (67) 157 (60)
Visual acuity reduced 81 (32) 82 (32) 85 (33)
Cataract 25 (10) 16 (6) 15 (6)
Eye irritation 19 (8) 27 (10) 7 (3)
Eye pain 14 (6) 18 (7) 9 (3)
Blepharitis 13 (5) 19 (7) 7 (3)
Choroidal
neovascularization
10 (4) 12 (5) 10 (4)
Macular degeneration 9 (4) 15 (6) 8 (3)
Vision blurred 11 (4) 9 (3) 7 (3)
Lacrimation
increased
8 (3) 15 (6) 2 (1)
Serious ocular AEs
in the
study eye, n (%)
0 (0) 3 (1) 4 (2)
Visual acuity reduced 0 (0) 1 (<1) 2 (1)
Cataract 0 (0) 0 (0) 1 (<1)
Macular edema 0 (0) 1 (<1) 0 (0)
Retinal detachment 0 (0) 1 (<1) 0 (0)
Hallucination, visual 0 (0) 0 (0) 1 (<1)
AEs ¼ adverse events; AL-8309B 1.75% ¼ AL-8309B
ophthalmic solution, 1.75%; AL-8309B 1.0% ¼ AL-8309B
ophthalmic solution, 1.0%; Vehicle¼AL-8309B ophthalmic solu-
tion vehicle.
Results are n (%).
Column header counts are the number of randomized and
treated patients. A patient is counted at most once in each
Medical Dictionary for Regulatory Activities system organ
class or preferred term row. Only preferred terms occurring
in at least 4% of 1 treatment group are presented for nonse-
rious AEs.stratified by GA lesion type, as determined by hyperauto-
fluorescence pattern, number and location of lesions, geno-
type, and SD OCT characteristics, may have provided
additional important information.VOL. 160, NO. 6 TANDOSPIRONE TRIAL FOR USECurrently, there are no approved treatments for
patients with GA associated with AMD. In eyes with
non-neovascular AMD, diverse causes of RPE cell
toxicity have been identified.29 Therefore, an agent
such as AL-8309B, which targets a specific cell stressor
such as oxidative injury, may not be sufficient to reverse
or prevent the damage to the cells caused by other fac-
tors. Additional candidate factors currently being inves-
tigated include components of the complement system,
which have been identified by genome-wide association
studies.3 The role of complement inhibition as a poten-
tial treatment for GA is supported by phase 2 results
from the MAHALO study (NCT01229215) demon-
strating that patients treated with lampalizumab (anti-
factor D) had a significant reduction in the GA area
enlargement at 18 months compared to placebo. In
contrast, in the COMPLETE study, systemic comple-
ment inhibition by eculizumab inhibiting complement
factor 5 did not decrease the growth rate of GA.30 There
are other clinical trial programs examining agents that
block different steps in the complement cascade or act
to preserve photoreceptor and RPE health.3,7 Drug
classes that maintain RPE and photoreceptor health by
decreasing cell stress and enhancing cell survival
remain important areas of investigation.29 We hypothe-
size that combination therapy with agents to target
different aspects of GA disease pathogenesis may be
more effective than monotherapy directed against
isolated biochemical pathways.
The GATE study is the largest clinical trial to date that
provides validated data regarding the rate of progression of
geographic atrophy lesions. This study included a standard-
ized follow-up protocol and software to quantify lesion size
in a semi-automated manner. The standardized and pro-
spective data acquisition of this clinical trial are of substan-
tial value to contribute to the understanding of the
pathophysiology and natural progression of GA. Addi-
tional analysis of data that may be of interest, including vi-
sual acuity loss data by baseline visual acuity, will be
presented in future manuscripts. Subsequent trials on GA
should take into consideration the limitations in the study
design discussed, including limited understanding of the
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